InsidersTradesSigma
Boston Scientific CORP Stock: price and management transactions · United States · SEC (Form 4)
Follow the Boston Scientific CORP stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Boston Scientific CORP has logged 588 reports. Market capitalisation: €67.1bn. The latest transaction was filed on 2 July 2026 (Levée d'options). Among the most active insiders: Mahoney Michael F. All data is openly available.
588
Insider Decl.
0
Thresholds
€2m
8 ops.
Buy Volume
€99m
128 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Boston Scientific CORP Strong Buy (bullish), based on 29 analysts. Average price target: US$75.00.
52Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 7,031 of 25,514 companies
62.9
score / 100
Value54
Quality72
FCF yld5.1%
Earn yld4.3%
EV/EBITDA15.4x
ROE15%
Gross mgn69%
Net mgn14%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 2 July 2026
Declarations588 total
2,087 sharesCommon StockSEC:0001225208-26-006362:0
1,010 sharesCommon StockSEC:0001225208-26-006362:1
386,755 shares0Common StockSEC:0001225208-26-005670:0
2,250 shares@ US$55.91950.0001% mcap50.1% of flowCommon StockSEC:0001225208-26-005546:1
Ideal exit: 14 Feb 2027 (T+270)
3,580 shares@ US$56.680.0001% mcap14.1% of flowCommon StockSEC:0001225208-26-005547:0
Ideal exit: 14 Feb 2027 (T+270)
1,770 shares@ US$56.490.0001% mcap100.0% of flowCommon StockSEC:0001225208-26-005548:0
Ideal exit: 14 Feb 2027 (T+270)
2,200 shares@ US$56.94510.0001% mcap49.9% of flowCommon StockSEC:0001225208-26-005546:0
Ideal exit: 13 Feb 2027 (T+270)
6,952 shares@ US$27.093.1% of flowCommon StockSEC:0001225208-25-009597:0
6,175 shares@ US$24.552.5% of flowCommon StockSEC:0001225208-25-009597:1
3,177 shares@ US$22.711.2% of flowCommon StockSEC:0001225208-25-009597:2
1,009 shares@ US$17.260.3% of flowCommon StockSEC:0001225208-25-009597:3
17,313 shares@ US$101.553128.6% of flowCommon StockSEC:0001225208-25-009597:4
50,000 shares@ US$26.154.3% of flowCommon StockSEC:0001225208-25-008911:0
3,600 shares@ US$100.74811.2% of flowCommon StockSEC:0001225208-25-008911:1
16,928 shares@ US$99.76075.6% of flowCommon StockSEC:0001225208-25-008911:2
29,472 shares@ US$99.14149.7% of flowCommon StockSEC:0001225208-25-008911:3
12,891 shares0Common StockSEC:0001225208-25-008842
12,891 shares0Common StockSEC:0001225208-25-008842:0
9,990 shares@ US$101.131235.1% of flowCommon StockSEC:0001225208-25-008761:0
2,901 shares@ US$102.240210.3% of flowCommon StockSEC:0001225208-25-008761:1
4,000 shares@ US$104.591929.7% of flowCommon StockSEC:0001225208-25-005546:0
4,826 shares@ US$106.4215.5% of flowCommon StockSEC:0001225208-25-005376:0
2,081 shares0Common StockSEC:0001225208-25-004935:0
2,081 shares0Common StockSEC:0001225208-25-004928:0
2,081 shares0Common StockSEC:0001225208-25-004931:0
25 of 588 declarations
About Boston Scientific CORP
Boston Scientific Corp. is a global medical technology company listed in the United States on the NYSE under the ticker BSX. For French-speaking investors, it is a large-cap healthcare name exposed to structurally attractive end markets driven by aging populations, the rise of chronic disease, and continuous innovation in minimally invasive care. The company was founded in 1979 in Watertown, Massachusetts, and today has its world headquarters in Marlborough, Massachusetts, in the United States. Its corporate identity was built around interventional medicine, with a strategy focused on differentiated technologies and clinical niches where product innovation, physician adoption, and regulatory clearance create meaningful barriers to entry. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai)) Boston Scientific reports through two major segments: MedSurg and Cardiovascular. Its portfolio spans electrophysiology and cardiac rhythm management, left atrial appendage closure, coronary and peripheral interventions, endoscopy, urology, and neuromodulation, along with certain minimally invasive surgical solutions. This diversification gives the company a resilient profile while also supporting above-average growth through a mix of mature franchises and newer platforms. Key product families include WATCHMAN, FARAPULSE, EKOS, EMBLEM MRI S-ICD, and a broad range of endoscopy and urology systems. ([news.bostonscientific.com](https://news.bostonscientific.com/interested-in-our-q4-2024-financial-results?utm_source=openai)) From a competitive standpoint, Boston Scientific ranks among the leading global players in implantable and interventional medical devices, competing with companies such as Medtronic, Abbott, Johnson & Johnson, and Edwards depending on the end market. Its edge comes from portfolio expansion, a strong innovation engine, and disciplined commercial execution across hospitals, electrophysiologists, interventional cardiologists, gastroenterologists, and urologists. The group also has a broad international footprint, with sales across multiple geographies and manufacturing and assembly capacity spread over several sites worldwide. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai)) Recent developments reinforce that thesis. Boston Scientific reported first-quarter 2026 net sales of $5.203 billion, up 11.6% year over year, and fourth-quarter 2025 sales of $5.286 billion, with full-year 2025 revenue reaching $20.074 billion. The company also released positive clinical data for FARAPULSE and WATCHMAN, received FDA approvals and clearances for several products, and announced acquisitions including Bolt Medical. For investors, BSX remains a high-quality Healthcare / Pharma stock combining organic growth, innovation, and portfolio leverage on a liquid, closely followed U.S. equity market. ([news.bostonscientific.com](https://news.bostonscientific.com/2026-04-22-Boston-Scientific-announces-results-for-first-quarter-2026?utm_source=openai))
